Episode

MASLD with Sven Francque - Part 2

Podcast
UEG Podcast
Published
Jun 2, 2026
Duration seconds
1685
Processing state
not_requested
Canonical source
https://ueg-talks-podcast.podigee.io/77-new-episode
Audio
https://audio.podigee-cdn.net/2486218-m-71df6806d0c81c8df1c3411d8ce59a5b.mp3?source=feed
JSON
/v1/public/podcasts/ueg-podcast-6404464/episodes/masld-with-sven-francque-part-2
Markdown
/podcast/ueg-podcast-6404464/masld-with-sven-francque-part-2.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/masld-with-sven-francque-part-2/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/ueg-podcast-6404464/masld-with-sven-francque-part-2.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

The 2024 MASLD treatment guidelines are already changing. Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, cover weight-loss targets (7% and 10%), resmetirom in F2-F3 fibrosis, semaglutide's positive phase 3 in MASH, plus pioglitazone, bariatric surgery, and liver transplantation in this population.